Reading JYNT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track JYNT free→Reading JYNT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track JYNT free→NASDAQHealth CareMedical Care FacilitiesSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but management's recent track record has been unsteady, with frequent disruptive corporate changes. Earnings quality is mixed, and risk is elevated, while the sector backdrop is a headwind. Peer multiples imply a price about 205% below where it trades (it looks expensive on this basis); the read is rich, as it trades above peer multiples, and the longer horizon does not make that back through growth. Key factors to watch include any potential guidance cuts and the performance of sector bellwethers like HCA, THC, and DVA. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 6 valuation methods, at three horizons. Current price $9.22. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $9.22, JYNT's earnings are too small for P/E to mean much; on sales it trades at 44× p/e (3.0× the 15× p/e peer median). At a normal multiple the price implies ~205% near-term growth vs our ~-29% forecast. That gap is an optionality premium a financial-multiple model can't price — our $3.02 fair value covers only the as-is business, low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 205% near-term growth, well above our forecast of about -29%. This describes what's priced in, not a forecast of the move.
Flags: expensive valuation, weak execution quality, a turbulent sector regime (Heating).
For similar setups historically (n=889): about 49% saw a 20%+ drawdown, and roughly 85% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 1.25x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.04 → $0.07 (+68.8% / 30d). 0 raised, 1 cut, 4 covering analysts.
0 upgrades, 0 downgrades / 30d. 25% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$124.
How much price usually moves either way.
On a bad day, this stock has moved -$400.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,708.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: The earnings report will show how the company is doing. It will also give future guidance.
Confirms one read:Earnings report shows revenue growth above 5% year over year.
Confirms the other:Earnings report shows revenue growth below 0% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for JYNT yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Facilities.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
JYNT Joint Corp. (The) | Typical Show detailsSector percentile: 44 of 100 | expensive | elevated |
HCA HCA Healthcare | Above typical Show detailsSector percentile: 81 of 100 | fair | moderate |
THC Tenet Health | Above typical Show detailsSector percentile: 87 of 100 | fair | elevated |
EHC Encompass Health | Above typical Show detailsSector percentile: 97 of 100 | full | moderate |
UHS Universal Health Services | Above typical Show detailsSector percentile: 93 of 100 | inexpensive | elevated |
19 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Increase the number of new franchised clinic openings to between 30 and 35 in 2026.
Stated in 2 of last 2 quarters. Management has consistently guided for 30 to 35 new franchised clinic openings in 2026. This represents a slight increase from 29 openings in 2025, indicating a focus on growth. However, the financials do not yet show a significant impact from this initiative, suggesting limited progress so far.
“New franchised clinic openings expected to be in the range of 30 to 35.”
“New franchised clinic openings expected to be in the range of 30 to 35.”
Maintain system-wide sales guidance between $519 million and $552 million for 2026.
Stated in 2 of last 2 quarters. Revenue for 2026-Q1 was $14.82M, which is a small portion of the annual guidance range of $519M to $552M. The company needs to significantly increase revenue in subsequent quarters to meet this target, indicating limited progress so far.
Why it matters: If revenue growth picks up, it could signal a stronger market for Joint Corp. and its peers.
Confirms:Health Care sector revenue growth is speeding up again. It is close to 10% year over year.
Disproves:Revenue growth is slowing down. It is now below 10% year over year.
Entry Into a Material Definitive Agreement. The information set forth below under
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On May 1, 2026, we entered into a waiver and fourth amendment to our existing credit agreement (the “2026 Amendment”) with JPMorgan Chase Bank, N.A., individually and as Administrative Agent, Issuing Bank, and Lender (“JPMorgan Chase” or the “Lender”). Among other things, the 2026 Amendment waives the existing default of our credit facilities due to a violation of our fixed charg…
Entry Into a Material Definitive Agreement. On April 20, 2026, we entered into an Asset Purchase Agreement (the “Elite Chiro Group Purchase Agreement”) with Elite Chiro Group, a California corporation (“Elite Chiro Group”), as buyer, and Gadi Emein, an individual (“Emein”), as guarantor, pursuant to which we will sell to Elite Chiro Group the assets of, and grant franchise rights to, 45 company-owned or managed clinics located in Southern California (the “Elite Chiro Group Transaction”) for a…
and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
“System-wide sales expected to be between $519 million and $552 million.”
“System-wide sales expected to be between $519 million and $552 million.”